- Trial Phase
- Phase 3 (registration-directed / confirmatory trials ongoing)
- Time to Market
- Not yet filed with FDA. An NDA would only follow the 2H26 (Study 304) and 1H27 (Study 306) readouts, putting earliest potential approval around 2028; no PDUFA date exists.
- Why 8/10
- The next hard, dated binary is topline data from confirmatory Phase 3 Study 304 (male pattern hair loss), guided for 2H 2026 (~by December 2026, ~4 months out), followed by the registration-directed Phase 2/3 Study 306 topline in 1H 2027 — and VDPHL01 is effectively the entire value of this ~$4.6B-market-cap, single-program company, so an 8 (dated binary within ~6 months on the lead asset driving the whole thesis).
Watch the 2H26 Study 304 topline and Study 302 12-month data, then the 1H27 Study 306 readout — these are the only real stock drivers for a company with zero revenue. In parallel, monitor the Aug 2026 resale S-1 (~40.6% of shares outstanding registered by holders incl. Longitude Capital and J.W. Childs) and the ~$10.7M August insider sale; supply overhang plus rising short interest (11.54% of est. shares outstanding at 7/31/26) can cap upside even on good data.
Price Chart
Executive Summary
VDPHL01 is Veradermics' (NYSE: MANE) lead and essentially only program: an oral extended-release minoxidil pill for pattern hair loss in men and women, developed by a company that IPO'd in April 2026 and is already valued at roughly $4.6B. Clinical data so far are consistently positive — a Phase 2/3 male study hit all primary and key secondary endpoints, and a Phase 2 female study showed double-digit hair-count gains at Month 6 — and two pivotal readouts are scheduled (Study 304 topline 2H26, Study 306 topline 1H27). The offsetting risks are pure share-structure and financing: an August 2026 resale S-1 registered ~40.6% of shares outstanding for sale by holders (company gets no proceeds), a director sold ~$10.7M of stock in mid-August, short interest stood at 11.54% of estimated shares outstanding (7/31/26 settlement) and rising, and there is zero revenue with widening losses.
How It Works
Minoxidil is the long-established hair-growth compound (the active ingredient in topical Rogaine); VDPHL01 is a new once-daily oral extended-release pill version of the same molecule, developed to treat male and female pattern hair loss with a pill instead of a daily scalp treatment.
Trial Status
Positive Phase 2/3 Study 302 topline in males (all primary and key secondary endpoints met, high statistical significance, April 2026); positive Phase 2 Study 207 topline in females (mean TAHC +22.7-23.3 hairs/cm², ~90% PRO response at Month 6, July 2026); enrollment completed for registration-directed Phase 2/3 Study 306 in females (556 participants), topline expected 1H 2027; confirmatory Phase 3 Study 304 (males) and 12-month Study 302 data expected 2H 2026; an earlier Phase 2 (NCT06527365, N=70, males and females with androgenetic alopecia) is active/not recruiting with estimated primary completion Aug 2026.
The Two-Sided Case
Upcoming Catalysts
- Topline data, confirmatory Phase 3 Study 304 (male pattern hair loss) — 2H 2026
- 12-month data from Phase 2/3 Study 302 (males) — 2H 2026
- Topline data, registration-directed Phase 2/3 Study 306 (female pattern hair loss, N=556) — 1H 2027
- Secondary sales under the Aug 2026 resale S-1 (~40.6% of shares outstanding registered) — ongoing overhang
- Any FDA/regulatory meeting updates following the readouts
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Veradermics, Inc 8-K MANE ·Originating report